Braxia Scientific Corp.
BRAXF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.05 | 0.02 | -0.00 |
| FCF Yield | -36.08% | -3.95% | -9.07% | -19.82% |
| EV / EBITDA | -2.49 | -19.68 | -7.39 | -2.61 |
| Quality | ||||
| ROIC | -360.84% | -21.85% | -78.87% | -123.97% |
| Gross Margin | 16.65% | 0.76% | -22.23% | -192.44% |
| Cash Conversion Ratio | 0.59 | 0.52 | 0.70 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.43% | 18.48% | 20.22% | 23.17% |
| Free Cash Flow Growth | -282.76% | 75.03% | 58.00% | 62.85% |
| Safety | ||||
| Net Debt / EBITDA | -0.63 | 0.94 | 1.04 | 0.59 |
| Interest Coverage | -38.06 | -10.03 | -187.89 | -738.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -6,302,031,283,224,576.00 | 176.08 |
| Cash Conversion Cycle | -288.84 | -187.38 | -142.60 | 6.67 |